ADAMDEC1 and central nervous system cancer: Further investigation of these candidates using TCGA datasets revealed that ADAM members (8, 9, 12, 15, 19, 32, 33), ADAMTS members (1, 2, 3, 4, 7, 9, 14, 18), ADAMTSL4, and ADAMDEC1 showed increased expression associated with poorer prognosis of GBM patients, while ADAM members (11, 20, 22, 23, 29), ADAMTS members (5, 6, 8, 10, 12, 13, 17, 19, 20), and ADAMTSL (2, 3, 5) showed decreased expression associated with poorer prognosis of glioma patients (Figure 2).